NCT04656951View on ClinicalTrials.gov

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

PHASE2RecruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Multiple Myeloma

Interventions

DRUG

Daratumumab

Daratumumab added to induction regimen of bortezomib, cyclophosphamide and dexamethasone (VCD), to bortezomib and dexamethasone during maintenance and to lenalidomide and dexamethasone at progression/relapse.

Trial Locations (1)

50937

RECRUITING

University of Cologne, Cologne

All Listed Sponsors

collaborator

Janssen-Cilag G.m.b.H

INDUSTRY

lead

University of Cologne

OTHER